InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Share Price

- Current share price for CUV : $9.980

CLINUVEL (CUV), an ASX-listed company, is a pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photo medicine and the family of melanocortin peptides

CUV General Information +

ASX Code CUV
Website http://www.clinuvel.com
Industry/Sector Biotechnology
Market Cap ($M) 503
CUV Share Price $9.980
Day High $10.100
Day Low $9.720
Last Close $9.980
CUV Share Price Movement - ( No change )
Prices as at 16:40, 15 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Clinuvel Pharmaceuticals Limited (CUV) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
HFResult 5¢ 100% 4 Sep 2025 19 Sep 2025 - - -
HFResult 5¢ 100% 5 Sep 2024 20 Sep 2024 - - -
HFResult 5¢ 100% 5 Sep 2023 20 Sep 2023 - - -

See all dividends from Clinuvel Pharmaceuticals Limited (CUV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Clinuvel Pharmaceuticals Limited (CUV) price-sensitive announcements

CUV - SCENESSE approved for EPP in Canada
Clinuvel Pharmaceuticals Limited announced that its novel drug SCENESSE® (afamelanotide) h
Clinuvel Pharmaceuticals Limited (CUV)
13 Jul 2026 | 8:34 AM
CUV - CLINUVEL publicly files 20-F to U.S. SEC
Clinuvel Pharmaceuticals Limited announced the public filing of its Form 20-F Registration
Clinuvel Pharmaceuticals Limited (CUV)
16 Jun 2026 | 9:06 AM
CUV - CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
Clinuvel Pharmaceuticals Limited announced its engagement with the U.S. Securities and Exc
Clinuvel Pharmaceuticals Limited (CUV)
28 Apr 2026 | 8:50 AM
CUV - FDA relaxes SCENESSE postmarketing requirement
Clinuvel Pharmaceuticals Limited has announced that the U.S. FDA has reviewed and subseque
Clinuvel Pharmaceuticals Limited (CUV)
27 Apr 2026 | 8:42 AM

Clinuvel Pharmaceuticals Limited (CUV) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $503 SCENESSE approved for EPP in Canada 13 Jul 2026 8:34AM $10.270 $9.980 fallen by 2.82%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $503 CLINUVEL confirms terms of CEO's Employment Agreement 2 Jul 2026 11:36AM $10.350 $9.980 fallen by 3.57%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $503 CLINUVEL publicly files 20-F to U.S. SEC 16 Jun 2026 9:06AM $9.250 $9.980 risen by 7.89%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $503 CLINUVEL US Non-Deal Roadshow Presentation 2 Jun 2026 9:26AM $9.260 $9.980 risen by 7.78%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $503 Notification regarding unquoted securities - CUV 7 May 2026 11:45AM $9.490 $9.980 risen by 5.16%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $503 CLINUVEL update on Level II ADR upgrade, Nasdaq uplist 28 Apr 2026 8:50AM $8.980 $9.980 risen by 11.14%

CUV Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A $36.17 $71.80 2.90% 17.60 5.00 0.40% 100.0%
2024A $35.64 $69.80 18.10% 23.10 5.00 0.30% 100.0%
2023A $30.60 $59.10 46.70% 33.80 5.00 0.30% 100.0%

CUV Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
CSL Limited (CSL) $58,887M 0.1108 -0.1192 0.0168 13.1851 14.9696 14.7228 3.63% 2.97% 3.08%
Clinuvel Pharmaceuticals Limited (CUV) $514M 0.0287 0.0000 0.0000 14.1922 0.0000 0.0000 0.49% 0.00% 0.00%
Immutep Limited (IMM) $81M 0.1854 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $3,081M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,362M -1.3893 0.0000 -0.1300 0.0000 289.0110 332.2105 0.00% 0.00% 0.00%

CUV Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.20 13.90 2.08 0.00
Market 0.30 13.10 1.14 0.60
Sector 0.46 27.80 2.48 1.96

CUV Directors

Name Position Start Date
Dr Philippe J Wolgen Chief Executive Officer, Managing Director 1 Oct 2005
Professor Jeffrey Rosenfeld Non-Executive Chairman, Non-Executive Director 26 Nov 2019
Mrs Susan (Sue) Smith Non-Executive Director 23 Sep 2019
Dr Karen Agersborg Non-Executive Director 29 Jan 2018
Mr Matthew William Pringle Non-Executive Director 6 Sep 2024
Dr Pearl E Grimes Non-Executive Director 6 Sep 2024
Mr Guy van Dievoet Non-Executive Director 6 Sep 2024

Clinuvel Pharmaceuticals Limited (CUV) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
19 Sep 2023 WOLGEN, Philippe Buy Direct Shares 1,850 $16.116 $29,813.860
26 Jun 2023 WOLGEN, Philippe Buy Direct Shares 1,532 $17.720 $27,147.330
4 Nov 2022 ROSENFELD, Jeffrey Buy Indirect Shares 300 $19.440 $5,832.000

See all changes in directors' interest & trades for Clinuvel Pharmaceuticals Limited (CUV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CUV Management

Name Position
Mr P Vaughan Chief Financial Officer
Mr L Hay Chief Operating Officer
Dr D Wright Chief Scientific Officer
Claire Newstead-Sinclair Company Secretary

CUV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clinuvel Pharmaceuticals Limited (CUV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
3,854,043 (7.69%) The Bank of New York Mellon Corporation
3,425,222 (6.83%) Dr Philippe Jacques Wolgen
2,340,824 (4.67%) Ender 1, LLC and SNP Ventures Group Member

CUV Calendar of Events

Date Event
25 February 2027 Report (Interim)
28 August 2026 Report (Prelim)
27 August 2026 Report (Annual)
27 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.